^
Association details:
| Biomarker: | PD-L1 negative |
|---|---|
| Cancer: | Squamous Cell Carcinoma of Head and Neck |
| Drug: | Erbitux (cetuximab) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Excerpt:
A summary of management strategies for recurrent and/or metastatic SCCHN...No platinum-based ChT during the last 6 months and PD-L1-negative tumour...Options...Methotrexate or taxane or cetuximab and/or BSC in case of contraindication to immunotherapy and unfit for platinum-based therapy...
DOI:
10.1016/j.annonc.2020.07.011
